Imidazopyridine compound

Abstract

A compound represented by the following general formula (1), or a salt or hydrate thereof: wherein R 1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R 2 represents a hydrogen atom or a C1-C6 alkyl group, R 3 represents methyl or ethyl group, R 4 represents a C1-C6 alkyl group, R 5 represents a hydrogen atom, provided that a compound wherein R 1 is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R 2 is a hydrogen atom is excluded.

1 . A compound represented by the following formula (1), or a salt thereof or a hydrate thereof: 
 [Formula 1]                         wherein R 1  represents a C1-C6 alkyl group which may have at least one substituent selected from the following α group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C3-C6 cycloalkyl group, or a phenyl group which may have a substituent selected from the following β group; 
 R 2  represents a hydrogen atom or a C1-C3 alkyl group;  
 R 3  represents a methyl or ethyl group;  
 R 4  represents a C1-C6 alkyl group;  
 R 5  represents a hydrogen atom;  
 α group is a halogen atom, a C3-C6 cycloalkyl group, a phenyl group which may have at least one substituent selected from the following β group or a phenyloxy group which may have a substituent selected from the following β group;  
 β group is a halogen atom or a C1-C6 alkoxy group;  
 provided that a compound wherein R 1  is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R 2  is a hydrogen atom is excluded.  
   
     
     
         2 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 1  is an unsubstituted C1-C6 alkyl group.  
     
     
         3 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 1  is a C2-C6 alkynyl group.  
     
     
         4 . The compound or a salt thereof or a hydrate thereof of according to  claim 1 , wherein R 1  is a C1-C6 alkyl group which may be substituted with halogen.  
     
     
         5 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 1  is a phenyl group which may have a substituent selected from the β group.  
     
     
         6 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 1  is a methyl group, 2,2,2-trifluoroethyl group, 2,2-difluoroethyl group, 2-(phenyl)propyl group, 2-(phenyloxy)ethyl group, 2-butynyl group, 3-fluorophenyl group, 4-fluorophenyl group, or 4-methoxyphenyl group.  
     
     
         7 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 1  is a methyl group, 2,2,2-trifluoroethyl group or 2,2-difluoroethyl group.  
     
     
         8 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 2  is a hydrogen atom, methyl group, ethyl group or propyl group.  
     
     
         9 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 2  is a methyl group.  
     
     
         10 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 2  is a hydrogen atom.  
     
     
         11 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 3  is a methyl group.  
     
     
         12 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , wherein R 4  is a methyl group.  
     
     
         13 . The compound or a salt thereof or a hydrate thereof according to  claim 1 , said compound is selected from the group consisting of the following compounds: 
 5-methoxy-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-6-methyl-3H-imidazo[4,5-b]pyridine,    2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl]-6-methyl-5-(2,2,2-trifluoroethoxy)-3H-imidazo[4,5-b]pyridine, and    5-(2,2-difluoroethoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-6-methyl-3H-imidazo[4,5-b]pyridine.    
     
     
         14 . A pharmaceutical composition which comprises a compound or a salt thereof or a hydrate thereof according to  claim 1 , and a pharmaceutically acceptable carrier.  
     
     
         15 . The pharmaceutical composition according to  claim 14 , wherein the disease caused by gastric acid is gastric ulcer, duodenal ulcer, stomal ulcer, gastroesophageal reflux disease, Zollinger-Ellison syndrome, symptomatic gastroesophageal reflux disease, endoscopy-negative gastroesophageal reflux disease, gastroesophageal regurgitation, paresthesia of pharyngolarynx, Barrett's esophagus, non-steroidal antiinflammatory drug (NSAID) ulcer, gastritis, stomach bleeding, gastrointestinal bleeding, peptic ulcer, bleeding ulcer, stress ulcer, gastric hyperacidity, dyspepsia, gastroparesis, senile ulcer, intractable ulcer, heartburn, bruxism, stomachache, heavy stomach, temporomandibular arthrosis or erosive gastritis.  
     
     
         16 . The pharmaceutical composition according to  claim 14 , wherein the disease caused by gastric acid is gastric ulcer, duodenal ulcer, stomal ulcer, gastroesophageal reflux disease, Zollinger-Ellison syndrome or symptomatic gastroesophageal reflux disease.  
     
     
         17 . The pharmaceutical composition according to  claim 14 , wherein the disease caused by gastric acid is gastroesophageal reflux disease or symptomatic gastroesophageal reflux disease.  
     
     
         18 . The pharmaceutical composition according to  claim 14 , wherein the disease caused by gastric acid is gastric ulcer or duodenal ulcer.  
     
     
         19 . A mono therapeutic or combination therapeutic agent for eradication of  Helicobacter Pylori  in a stomach which comprises the compound or a salt thereof or a hydrate thereof according to  claim 1.